Search Results - "Cebrian, I. Gonzalez"

P-145Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis by Munoz, A, Ruiz Casado, A, Pericay, C, Ibeas Millan, P, Grandez Ladron de Guevara, R, Diaz Pena, E, Lopez Munoz Ana, M, Gonzalez Cebrian, I, Moreno Santos Ma, A, Juez Martel, I, Encinas Garcia, S, Alcaide Garcia, J, Bruquetas, Machengs, Garcia Adrian, S, Lobo de Mena, M, Higuera, O, Ghanem, I, Garcia Alfonso, P, Rodriguez, N

Get full text

P-129 Cisplatin plus Gemcitabine in Elderly patients with advanced biliary tract carcinoma: Torrecardenas Hospital Experience by Castellon Rubio, V.E., Gonzalez Cebrian, I., Canosa Ruiz, L.

Get full text

Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population by Carnerero Córdoba, L., González Cebrián, I., Rodríguez González, C., González-Flores, E., Conde, V., Delgado Ureña, M., Jurado García, J., González-Astorga, B.

Get full text

8532 Prognostic impact of comorbidity in elderly patients with head and neck squamous cell carcinoma (HNSCC) by Jimenez, M.A. Moreno, Cebrian, I. Gonzalez, Martin, R. Collado, Magan, B. Medina, Granados, A.L. Ortega, Salido, M.J. Mateos, Calderon, R. Alonso, Plata, Y

Get full text

P-389Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population by Carnerero Córdoba, L, González Cebrián, I, Rodríguez González, C, González-Flores, E, Conde, V, Delgado Ureña, M, Jurado García, J, González-Astorga, B

Get full text

216PUsefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab by Blancas, I, Martín, C, Martín-Pérez, F J, Legerén, M, Martos, M, Sequero, S, Carnenero, S, Pérez-García, M E, Rodríguez-González, C J, Jurado, J M, Delgado, M, González-Astorga, B, González-Cebrián, I, Garrido, J M, Prieto, C, Bayo-Martin, V, Fernández-Gutiérrez, M I, Ayala-Carbonero, G, Reyes-Larzategui, S, Rodríguez-Serrano, F

“…Abstract Background Trastuzumab is a highly efficient drug in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most…”
Get full text

Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab by Blancas, I., Martín, C., Martín-Pérez, F.J., Legerén, M., Martos, M., Sequero, S., Carnenero, S., Pérez-García, M.E., Rodríguez-González, C.J., Jurado, J.M., Delgado, M., González-Astorga, B., González-Cebrián, I., Garrido, J.M., Prieto, C., Bayo-Martin, V., Fernández-Gutiérrez, M.I., Ayala-Carbonero, G., Reyes-Larzategui, S., Rodríguez-Serrano, F.

Get full text

216P - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab by Blancas, I., Martín, C., Martín-Pérez, F.J., Legerén, M., Martos, M., Sequero, S., Carnenero, S., Pérez-García, M.E., Rodríguez-González, C.J., Jurado, J.M., Delgado, M., González-Astorga, B., González-Cebrián, I., Garrido, J.M., Prieto, C., Bayo-Martin, V., Fernández-Gutiérrez, M.I., Ayala-Carbonero, G., Reyes-Larzategui, S., Rodríguez-Serrano, F.

“…Trastuzumab is a highly efficient drug in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect…”
Get full text

P-145 Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis by Muñoz, A., Ruiz Casado, A., Pericay, C., Ibeas Millan, P., Grandez Ladrón de Guevara, R., Díaz Peña, E., Lopez Muñoz Ana, M., González Cebrián, I., Moreno Santos Ma, A., Juez Martel, I., Encinas García, S., Alcaide García, J., Machengs Bruquetas, I., García Adrián, S., Lobo de Mena, M., Higuera, O., Ghanem, I., García Alfonso, P., Rodriguez, N.

Get full text